Wednesday, 17 Oct 2018

You are here

Type I Interferon Drives Photosensitivity in Cutaneous Lupus

Kahlenberg and coworkers have reported in ARD that interferon kappa (IFN-κ) is a key regulator of type I interferon (IFN) photosensitive responses in patients with cutaneous lupus erythematosus (CLE).

They analyzed mRNA expression of type I IFN gene expression by microarrays of biopsied CLE lesions and healthy control skin. They also examined gene expression in cultured keratinocytes, fibroblasts and endothelial cells IFNK knock-out keratinocytes generated using CRISPR/Cas9. 

They discovered that IFNK is one of two type I IFNs significantly increased (1.5-fold change) in lesional CLE skin.

Type I IFN responses were enriched in keratinocytes, but not in fibroblast or endothelial cells, and that epithelial-derived IFN-κ is responsible for maintaining baseline type I IFN responses in healthy skin.

Increased levels of IFN-κ seen in SLE can amplify and accelerate responsiveness of epithelia to IFN-α and increase keratinocyte sensitivity to UV irradiation.

IFN-κ is a critical IFN in CLE pathology via promotion of enhanced IFN responses and photosensitivity and could therefore be a potential novel treatment target.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Teenage Obesity Increases Lupus Risk

Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.

The relationship between obesity and SLE risk is unclear. Past studies have predominantly assessed white women, while black women have higher prevalence of both obesity and SLE.

SLE-Scleroderma Overlap Outcomes

Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.

Excess Mortality in CTD or Systemic Vasculitis Patients

The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.

Mortality Improves in Lupus ESRD

The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.

Ustekinumab May be Effective in Lupus

Ronald F van Vollenhoven and colleagues have reported in Lancet that ustekinumab (UST), an interleukin-12 and -23 inhibitor, when added to usual therapy in systemic lupus erythematosus (SLE) patients, was shown to be superior to placebo at improving clinical efficacy and laboratory parameters after 6 months of therapy.